CD274 and neoplasm: Camrelizumab, as the first domestic anti-tumor PD-1 antibody, specifically targets PD-1 and blocks its binding to PD-L1 and programmed death ligand 2 (PD-L2), thereby restoring the body’s immune function and ultimately exerting anti-tumor effects.